Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment
The DOI matches its Crossref record; 482 of the 482 references it cites were found in a registry or an index.
Abstract
Drug-induced calculi represent 1-2% of all renal calculi. The drugs reported to produce calculi may be divided into two groups. The first one includes poorly soluble drugs with high urine excretion that favour crystallisation in the urine. Among them, drugs used for the treatment of patients with human immunodeficiency, namely atazanavir and other protease inhibitors, and sulphadiazine used for the treatment of cerebral toxoplasmosis, are the most frequent causes. Besides these drugs, about 20 other molecules may induce nephrolithiasis, such as ceftriaxone or ephedrine-containing preparations in subjects receiving high doses or long-term treatment. Calculi analysis by physical methods including infrared spectroscopy or X-ray diffraction is needed to demonstrate the presence of the drug or its metabolites within the calculi. Some drugs may also provoke heavy intra-tubular crystal precipitation causing acute renal failure. Here, the identification of crystalluria or crystals within the kidney tissue in the case of renal biopsy is of major diagnostic value. The second group includes drugs that provoke the formation of urinary calculi as a consequence of their metabolic effects on urinary pH and/or the excretion of calcium, phosphate, oxalate, citrate, uric acid or other purines. Among such metabolically induced calculi are those formed in patients taking uncontrolled calcium/vitamin D supplements, or being treated with carbonic anhydrase inhibitors such as acetazolamide or topiramate. Here, diagnosis relies on a careful clinical inquiry to differentiate between common calculi and metabolically induced calculi, of which the incidence is probably underestimated. Specific patient-dependent risk factors also exist in relation to urine pH, volume of diuresis and other factors, thus providing a basis for preventive or curative measures against stone formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The topiramate component of phentermine HCl/topiramate ER decreases renal tubule reabsorption of HCO3 and decreases excretion of H, contributing to metabolic acidosis, and increased urinary pH, which may increase the risk of kidney stones [27], with the most specific reported composition being calcium phosphate stones [28].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [27]
In the citing paper
“Orlistat increases unabsorbed intestinal fat which binds to intestinal calcium, with less calcium available to bind to intestinal oxalate. This allows for increased intestinal oxalate absorption that may ultimately cause hyperoxaluria, promoting calcium oxalate stones [27].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [27]
Citations
Cites
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Calcium plus Vitamin D Supplementation and the Risk of Fractures
Jackson, R. D., LaCroix, A. Z., Gass, M., Wallace, R. B., Robbins, J., Lewis, C. E., Bassford, T., Beresford, S. A. A., Black, H. R., Blanchette, P., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055218 · Cited by 1,883
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
The Pharmacology and Clinical Use of Methotrexate
Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J., & Chabner, B. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198311033091805 · Cited by 786
Campoli-Richards, D. M., Monk, J. P., Price, A., Benfield, P., Todd, P. A., & Ward, A. (1988) · Drugs · doi:10.2165/00003495-198835040-00003 · Cited by 749
Understanding and Managing Methotrexate Nephrotoxicity
Widemann, B. C., & Adamson, P. C. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-694 · Cited by 730
Mutations in CYP24A1 and Idiopathic Infantile Hypercalcemia
Schlingmann, K. P., Kaufmann, M., Weber, S., Irwin, A., Goos, C., John, U., Misselwitz, J., Klaus, G., Kuwertz-Bröking, E., Fehrenbach, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103864 · Cited by 691
HIV-1 protease inhibitors. A review for clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.277.2.145 · Cited by 675
Lodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009) · Clinical Infectious Diseases · doi:10.1086/600884 · Cited by 554
Molina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61081-8 · Cited by 486
HIV-1 Protease Inhibitors: A Review for Clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.1997.03540260059037 · Cited by 434
Antiviral Drug-Induced Nephrotoxicity
Izzedine, H., Launay-Vacher, V., & Deray, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.02.010 · Cited by 423
Twenty-four–hour urine chemistries and the risk of kidney stones among women and men
Curhan, G. C., Willett, W. C., Speizer, F. E., & Stampfer, M. J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00746.x · Cited by 394
Clumeck, N., Pozniak, A., Raffi, F., & the EACS Executive Committee (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2007.00533.x · Cited by 383
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy
Hoffer, L. J., Levine, M., Assouline, S., Melnychuk, D., Padayatty, S. J., Rosadiuk, K., Rousseau, C., Robitaille, L., & Miller, W. H. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn377 · Cited by 375
Herlitz, L. C., Mohan, S., Stokes, M. B., Radhakrishnan, J., D'Agati, V. D., & Markowitz, G. S. (2010) · Kidney International · doi:10.1038/ki.2010.318 · Cited by 348
Crystal-induced acute renal failure
Perazella, M. A. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00041-8 · Cited by 322
Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it?
Balakumar, P., Rohilla, A., & Thangathirupathi, A. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.04.004 · Cited by 318
Crystalluria and Urinary Tract Abnormalities Associated with Indinavir
Kopp, J. B., Miller, K. D., Mican, J. A. M., Feuerstein, I. M., Vaughan, E., Baker, C., Pannell, L. K., & Falloon, J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-2-199707150-00004 · Cited by 312
Kassahun, K., McIntosh, I., Cui, D., Hreniuk, D., Merschman, S., Lasseter, K., Azrolan, N., Iwamoto, M., Wagner, J. A., & Wenning, L. A. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016196 · Cited by 278
The association of nephrolithiasis with cystic fibrosis
Gibney, E. M., & Goldfarb, D. S. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00403-7 · Cited by 272
Renal Calcifications: A Complication of Long-Term Furosemide Therapy in Preterm Infants
Hufnagle, K. G., Khan, S. N., Penn, D., Cacciarelli, A., & Williams, P. (1982) · Pediatrics · doi:10.1542/peds.70.3.360 · Cited by 271
Urinary calculi: review of classification methods and correlations with etiology.
Daudon, M., Bader, C., & Jungers, P. (1993) · PubMed · Cited by 269
Self-citationBarry, M., Gibbons, S., Back, D., & Mulcahy, F. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00003 · Cited by 254
REVERSIBLE CEFTRIAXONE-ASSOCIATED BILIARY PSEUDOLITHIASIS IN CHILDREN
Schaad, U., Wedgwood-Krucko, J., & Tschaeppeler, H. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90596-x · Cited by 252
Thiazide Effect on the Mineral Content of Bone
Wasnich, R. D., Benfante, R. J., Yano, K., Heilbrun, L., & Vogel, J. M. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308113090605 · Cited by 251
Lappe, J., Watson, P., Travers-Gustafson, D., Recker, R., Garland, C., Gorham, E., Baggerly, K., & McDonnell, S. L. (2017) · JAMA · doi:10.1001/jama.2017.2115 · Cited by 247
Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration
Campieri, C., Campieri, M., Bertuzzi, V., Swennen, E., Matteuzzi, D., Stefoni, S., Pirovano, F., Centi, C., Ulisse, S., Famularo, G., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0600031097.x · Cited by 240
Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria
Sidhu, H., Hoppe, B., Hesse, A., Tenbrock, K., Bromme, S., Rietschel, E., & Peck, A. B. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03038-4 · Cited by 238
Evans, G. W., Phillips, G., Mukherjee, T. M., Snow, M. R., Lawrence, J. R., & Thomas, D. W. (1973) · Journal of Clinical Pathology · doi:10.1136/jcp.26.1.32 · Cited by 225
Acyclovir-induced renal failure
Sawyer, M. H., Webb, D. E., Balow, J. E., & Straus, S. E. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90313-0 · Cited by 222
Management of Acute and Chronic Gouty Arthritis: Present State-of-the-Art
Schlesinger, N. (2004) · Drugs · doi:10.2165/00003495-200464210-00003 · Cited by 220
3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Meibohm, A., Condra, J. H., Valentine, F. T., McMahon, D., Gonzalez, C., Jonas, L., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00007 · Cited by 204
Use of an automated external de fibrillation pacemaker by ambulance staff
Jaggarao, N. S. V., Heber, M. E., Grainger, R. M., Vincent, R. P., Chamberlain, D. A., & Aronson, A. L. (1982) · The Lancet · Cited by 200
Total, Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones
Ferraro, P. M., Curhan, G. C., Gambaro, G., & Taylor, E. N. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.09.005 · Cited by 196
Characterization and Some Physicochemical Aspects of Pathological Microcalcifications
Bazin, D., Daudon, M., Combes, C., & Rey, C. (2012) · Chemical Reviews · doi:10.1021/cr200068d · Cited by 192
Self-citationSidhu, H., Schmidt, M. E., Cornelius, J. G., Thamilselvan, S., Khan, S. R., Hesse, A., & Peck, A. B. (1999) · PubMed · Cited by 187
Safety of Topiramate: Adverse Events and Relationships to Dosing
Shorvon, S. D. (1996) · Epilepsia · doi:10.1111/j.1528-1157.1996.tb06029.x · Cited by 184
Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing
Markowitz, G. S., Nasr, S. H., Klein, P., Anderson, H., Stack, J. I., Alterman, L., Price, B., Radhakrishnan, J., & D’agati, V. D. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.12.005 · Cited by 181
Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy
Wong-Beringer, A., Joo, J., Tse, E., & Beringer, P. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.10.013 · Cited by 178
Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
Dieleman, J. P., Gyssens, I. C., E. van der Ende, M., de Marie, S., & Burger, D. M. (1999) · Aids · doi:10.1097/00002030-199903110-00005 · Cited by 178
Épidémiologie actuelle de la lithiase rénale en France
Daudon, M. (2005) · Annales d Urologie · doi:10.1016/j.anuro.2005.09.007 · Cited by 177
Self-citationA PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG
PERUCCA, E. (1997) · Pharmacological Research · doi:10.1006/phrs.1997.0124 · Cited by 176
Ko, C. W., Sekijima, J. H., & Lee, S. P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-4-199902160-00016 · Cited by 176
Effect of ascorbic acid consumption on urinary stone risk factors
TRAXER, O., HUET, B., POINDEXTER, J., PAK, C. Y. C., & PEARLE, M. S. (2003) · Journal of Urology · doi:10.1097/01.ju.0000076001.21606.53 · Cited by 169
Glaucoma and the Applications of Carbonic Anhydrase Inhibitors
Scozzafava, A., & Supuran, C. T. (2013) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-7359-2_17 · Cited by 167
Urinary Xanthine Stones-a Rare Complication of Allopurinol Therapy
Greene, M. L., Fujimoto, W. Y., & Seegmiller, J. E. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902202800806 · Cited by 165
Acute Phosphate Nephropathy and Renal Failure
Desmeules, S., Bergeron, M. J., & Isenring, P. (2003) · New England Journal of Medicine · doi:10.1056/nejm200309043491020 · Cited by 164
Drug-Induced Renal Calculi: Epidemiology, Prevention and Management
Daudon, M., & Jungers, P. (2004) · Drugs · doi:10.2165/00003495-200464030-00003 · Cited by 161
Self-citationOver the counter but no longer under the radar - pediatric cough and cold medications
Sharfstein, J. M., North, M., & Serwint, J. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmp0707400 · Cited by 158
The nephrotoxic effects of HAART
Izzedine, H., Harris, M., & Perazella, M. A. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.142 · Cited by 156
Drug-induced crystal nephropathy: an update
Yarlagadda, S. G., & Perazella, M. A. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.2.147 · Cited by 154
Vancomycin-Associated Cast Nephropathy
Luque, Y., Louis, K., Jouanneau, C., Placier, S., Estève, E., Bazin, D. C., Rondeau, É., Letavernier, E., Wolfromm, A., Gosset, C., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016080867 · Cited by 152
Self-citationNorfloxacin disposition after sequentially increasing oral doses
Swanson, B. N., Boppana, V. K., Vlasses, P. H., Rotmensch, H. H., & Ferguson, R. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.2.284 · Cited by 149
A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination
Hulot, J.-S., Villard, E., Maguy, A., Morel, V., Mir, L., Tostivint, I., William-Faltaos, D., Fernandez, C., Hatem, S., Deray, G., et al. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200505000-00002 · Cited by 143
CYP24A1 Mutations in a Cohort of Hypercalcemic Patients: Evidence for a Recessive Trait
Molin, A., Baudoin, R., Kaufmann, M., Souberbielle, J. C., Ryckewaert, A., Vantyghem, M. C., Eckart, P., Bacchetta, J., Deschenes, G., Kesler-Roussey, G., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4387 · Cited by 142
Vrouenraets, S. M. E., Wit, F. W. N. M., van Tongeren, J., & Lange, J. M. A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.6.851 · Cited by 142
Clinical Value of Crystalluria and Quantitative Morphoconstitutional Analysis of Urinary Calculi
Daudon, M., & Jungers, P. (2004) · Nephron Physiology · doi:10.1159/000080261 · Cited by 141
Self-citationFavre, L., GLASSON, P., & VALLOTTON, M. B. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-3-317 · Cited by 140
Schreiner, G. E., & Maher, J. F. (1965) · The American Journal of Medicine · doi:10.1016/0002-9343(65)90149-x · Cited by 139
Urinary stones in HIV-1-positive patients treated with indinavir
Daudon, M., Estepa, L., Viard, J., Joly, D. A., & Jungers, P. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62506-8 · Cited by 136
Self-citationSingle-Dose Pharmacokinetics of Indinavir and the Effect of Food
Yeh, K. C., Deutsch, P. J., Haddix, H., Hesney, M., Hoagland, V., Ju, W. D., Justice, S. J., Osborne, B., Sterrett, A. T., Stone, J. A., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.332 · Cited by 135
Daudon, M., Dessombz, A., Frochot, V., Letavernier, E., Haymann, J., Jungers, P., & Bazin, D. C. (2016) · Comptes Rendus Chimie · doi:10.1016/j.crci.2016.05.008 · Cited by 131
Self-citationAscorbic Acid Overdosing: A Risk Factor for Calcium Oxalate Nephrolithiasis
Urivetzky, M., Kessaris, D., & Smith, A. D. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37521-3 · Cited by 130
Assessment of the Role of Renal Organic Anion Transporters in Drug-Induced Nephrotoxicity
Hagos, Y., & Wolff, N. A. (2010) · Toxins · doi:10.3390/toxins2082055 · Cited by 129
Pharmacokinetic profile of ceftriaxone in man.
Patel, I. H., & Kaplan, S. A. (1984) · PubMed · Cited by 129
Kawai, K., Saathoff, E., Antelman, G., Msamanga, G., & Fawzi, W. W. (2009) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2009.80.36 · Cited by 129
Crystalluria: a neglected aspect of urinary sediment analysis
Fogazzi, G. B. (1996) · Nephrology Dialysis Transplantation · doi:10.1093/oxfordjournals.ndt.a027276 · Cited by 127
Biochemical and stone-risk profiles with topiramate treatment
Welch, B. J., Graybeal, D., Moe, O. W., Maalouf, N. M., & Sakhaee, K. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.07.003 · Cited by 126
Ascorbic Acid Supplements and Kidney Stone Incidence Among Men: A Prospective Study
Thomas, L. D. K., Elinder, C.-G., Tiselius, H.-G., Wolk, A., & Åkesson, A. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2296 · Cited by 126
The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Supuran, C. T., Scozzafava, A., & Mincione, F. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208783877866 · Cited by 125
Tashima, K. T., Horowitz, J. D., & Rosen, S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360215 · Cited by 120
Metabolic concerns associated with antiepileptic medications
Sheth, R. D. (2004) · Neurology · doi:10.1212/wnl.63.10_suppl_4.s24 · Cited by 119
Ma-huang strikes again: Ephedrine nephrolithiasis
Powell, T., Hsu, F., TURK, J. W., & Hruska, K. A. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9669437 · Cited by 118
Chan‐Tack, K. M., Truffa, M. M., Struble, K. A., & Birnkrant, D. B. (2007) · AIDS · doi:10.1097/qad.0b013e32813aee35 · Cited by 118
IMAGING CHARACTERISTICS OF INDINAVIR CALCULI
Schwartz, B. F., Schenkman, N. S., Armenakas, N. A., & Stoller, M. L. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)61596-9 · Cited by 114
Rao, N. P., Kavanagh, J. P., & Preminger, G. M. (2011) · Springer eBooks · doi:10.1007/978-1-84800-362-0 · Cited by 114
Chugh, S. S., Bird, R., & ALEXANDER, E. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360214 · Cited by 113
Jouret, F. C., Bernard, A., Hermans, C. R. J. R., Dom, G., Terryn, S., Leal, T., Lebecque, P., Cassiman, J. J., Scholte, B. J., de Jonge, H. R., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006030269 · Cited by 111
Iatrogenic Osteomalacia and Myopathy due to Phosphate Depletion
Baker, L. R. I., Ackrill, P., Cattell, W. R., Stamp, T. C. B., & Watson, L. (1974) · BMJ · doi:10.1136/bmj.3.5924.150 · Cited by 110
Osteomalacia with Pseudofractures Caused by the Ingestion of Aluminum Hydroxide
Bloom, W. L. (1960) · JAMA · doi:10.1001/jama.1960.63030100015026a · Cited by 107
Glauser, T. A. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00922.x · Cited by 104
Fine, A., & Patterson, J. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90015-9 · Cited by 100
Protease inhibitor-induced urolithiasis
Gentle, D. L., Stoller, M. L., Jarrett, T. W., Ward, J. F., Geib, K. S., & Wood, A. F. (1997) · Urology · doi:10.1016/s0090-4295(97)00401-9 · Cited by 96
Urolithiasis in HIV-Positive Patients Treated with Atazanavir
Couzigou, C., Daudon, M., Meynard, J., Lebas, F.-X., Higueret, D., Escaut, L., Zucman, D., Liotier, J.-Y., Quencez, J.-L., Asselah, K., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/521930 · Cited by 96
Self-citationEttinger, B. B., Oldroyd, N. O., & Sörgel, F. (1980) · JAMA · doi:10.1001/jama.1980.03310210045027 · Cited by 96
Secondary Hyperparathyroidism and Bone Disease in Infants Receiving Long-term Furosemide Therapy
Venkataraman, P. S., Han, B. K., Tsang, R. C., & Daugherty, C. C. (1983) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1983.02140380017006 · Cited by 95
Schell-Feith, E. A., Holthe, J. E. K., Conneman, N., van Zwieten, P. H. T., Holscher, H. C., Zonderland, H. M., Brand, R., & van der Heijden, B. J. (2000) · Kidney International · doi:10.1111/j.1523-1755.2000.00383.x · Cited by 93
Hamada, Y., Nishijima, T., Watanabe, K., Komatsu, H., Tsukada, K., Teruya, K., Gatanaga, H., Kikuchi, Y., & Oka, S. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis621 · Cited by 92
Herlitz, L., D’Agati, V. D., & Markowitz, G. S. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0565-ra · Cited by 92
Oxalate‐Degrading Enterococcus faecalis
Hokama, S., Honma, Y., Toma, C., & Ogawa, Y. (2000) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2000.tb02489.x · Cited by 89
Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children
Avcı, Z., Koktener, A., Uras, N., Catal, F., Karadag, A., Tekin, O., Degirmencioglu, H., & Baskin, E. (2004) · Archives of Disease in Childhood · doi:10.1136/adc.2003.044156 · Cited by 89
Russmann, S., Lamerato, L. E., Marfatia, A. A., Motsko, S. P., Pezzullo, J. C., Olds, G. D., & Jones, J. K. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01610.x · Cited by 88
Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants
Gimpel, C., Krause, A., Franck, P., Krueger, M., & von Schnakenburg, C. (2009) · Pediatrics International · doi:10.1111/j.1442-200x.2009.02886.x · Cited by 87
Adverse Renal and Metabolic Effects Associated with Oral Sodium Phosphate Bowel Preparation
Heher, E. C., Thier, S. O., Rennke, H. G., & Humphreys, B. D. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02040408 · Cited by 87
Acute interstitial nephritis associated with atazanavir, a new protease inhibitor
Brewster, U. C., & Perazella, M. A. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.07.017 · Cited by 86
Malek, R. S., & Kelalis, P. P. (1975) · The Journal of Urology · doi:10.1016/s0022-5347(17)59521-x · Cited by 86
Rockwood, N., Mandalia, S., Bower, M., Gazzard, B., & Nelson, M. R. (2011) · AIDS · doi:10.1097/qad.0b013e32834a1cd6 · Cited by 85
CLINICAL TOXICITY OF SULFONAMIDES
Lehr, D. E. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb49682.x · Cited by 84
Changes in renal function associated with indinavir
Boubaker, K., Sudre, P., Bally, F., Vogel, G. M. T., Meuwly, J., Glauser, M. P., & Telenti, A. (1998) · AIDS · doi:10.1097/00002030-199818000-00003 · Cited by 83
Osteomalacia due to phosphate depletion from excessive aluminium hydroxide ingestion.
Dent, C. E., & Winter, C. S. (1974) · BMJ · doi:10.1136/bmj.1.5907.551 · Cited by 83
Matlaga, B. R., Shah, O. D., & Assimos, D. G. (2003) · Europe PMC (PubMed Central) · Cited by 82
Rapidly Progressive Acute Renal Failure Due to Acyclovir: Case Report and Review of the Literature
Becker, B. N., Fall, P. J., Hall, C. L., Milam, D. F., Leonard, J., Glick, A. D., & Schulman, G. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80939-5 · Cited by 82
Chang, H. R., & Pella, P. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmc061892 · Cited by 82
Blake, S. P., McNicholas, M. M. J., & Raptopoulos, V. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.171.3.9725303 · Cited by 81
HIV and kidney diseases: 35 years of history and consequences
Campos, P., Ortíz, A., & Soto, K. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw104 · Cited by 81
Vitamin D Intake and the Risk of Incident Kidney Stones
Ferraro, P. M., Taylor, E. N., Gambaro, G., & Curhan, G. C. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.08.084 · Cited by 79
Laxative Abuse as a Cause for Ammonium Urate Renal Calculi
Dick, W. H., Lingeman, J. E., Preminger, G. M., Smith, L. H., Wilson, D. M., & Shirrell, W. L. (1990) · The Journal of Urology · doi:10.1016/s0022-5347(17)39923-8 · Cited by 78
Crystalluria and Ciprofloxacin, Influence of Urinary pH and Hydration
Þorsteinsson, S. B., Bergan, T., Oddsdottir, S., Rohwedder, R. W., & Holm, R. (2009) · Chemotherapy · doi:10.1159/000238444 · Cited by 78
Höppe, B., von Unruh, G., Blank, G., Rietschel, E., Sidhu, H., Laube, N., & Hesse, A. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.06.003 · Cited by 78
Daudon, M., Letavernier, E., Frochot, V., Haymann, J., Bazin, D. C., & Jungers, P. (2016) · Comptes Rendus Chimie · doi:10.1016/j.crci.2016.08.009 · Cited by 78
Self-citationExtreme Hyperphosphatemia and Acute Renal Failure after a Phosphorus-Containing Bowel Regimen
Orías, M., Mahnensmith, R. L., & Perazella, M. A. (1999) · American Journal of Nephrology · doi:10.1159/000013427 · Cited by 77
COMPLICATIONS FOLLOWING INTRAVENOUS ADMINISTRATION OF SOLUTIONS CONTAINING XYLITOL
Thomas, D. W., Edwards, J. B., Gilligan, J. E., LAWRENCE, J. R., & Edwards, R. G. (1972) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1972.tb116530.x · Cited by 76
Topiramate-Induced Nephrolithiasis
Kuo, R. L., Moran, M. E., Kim, D. H., Abrahams, H. M., White, M. D., & Lingeman, J. E. (2002) · Journal of Endourology · doi:10.1089/089277902753752188 · Cited by 76
Acute renal failure due to indinavir crystalluria and nephrolithiasis: Report of two cases
Berns, J. S., Cohen, R. M., Silverman, M. E., & Turner, J. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90316-4 · Cited by 75
A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease
Siva, S., Barrack, E. R., Reddy, G. P. V., Thamilselvan, V., Thamilselvan, S., Menon, M., & Bhandari, M. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08122.x · Cited by 75
Torres, R. J., Prior, C., & Puig, J. G. (2007) · Metabolism · doi:10.1016/j.metabol.2007.04.013 · Cited by 74
Acute Methotrexate-Induced Crystal Nephropathy
Garneau, A. P., Riopel, J., & Isenring, P. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1507547 · Cited by 74
Incidence of ceftriaxone-associated gallbladder pseudolithiasis
Papadopoulou, F., Efremidis, S. C., Karyda, S., Badouraki, M., Καρατζά, Ε., Panteliadis, C. P., & Malaka, K. (1999) · Acta Paediatrica · doi:10.1080/080352599750030077 · Cited by 73
KOHAN, A. D., Armenakas, N. A., & Fracchia, J. A. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68795-2 · Cited by 73
Ceftriaxone associated nephrolithiasis: a prospective study in 284 children
Mohkam, M., Karimi, A., Gharib, A., Daneshmand, H., Khatami, A., Ghojevand, N., & Sharifian, M. (2007) · Pediatric Nephrology · doi:10.1007/s00467-006-0401-2 · Cited by 72
Ceftriaxone-induced Cholelithiasis
Lopez, A. J., O’Keefe, P., Morrissey, M., & Pickleman, J. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-712 · Cited by 72
Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C
Auer, Auer, & Rodgers (1998) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1998.00349.x · Cited by 72
Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
Balani, S. K., Arison, B. H., Mathai, L., Kauffman, L. R., Miller, R. R., Stearns, R. A., Chen, I. W., & Lin, J. H. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06530-4 · Cited by 72
Acetazolamide and Urolithiasis
Kass, M. A., Kolker, A. E., Gordon, M. O., Goldberg, I., Gieser, D. K., Krupin, T., & BECKER, B. A. (1981) · Ophthalmology · doi:10.1016/s0161-6420(81)35041-6 · Cited by 71
Hootkins, R. E., Fenves, A. Z., & Stephens, M. K. (1989) · PubMed · Cited by 70
Dell'Orto, V. G., Belotti, E. A., Goeggel-Simonetti, B., Simonetti, G. D., Ramelli, G. P., Bianchetti, M. G., & Lava, S. A. G. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12283 · Cited by 69
Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis
de Moor, R. A., Egberts, T. C. G., & Schröder, C. H. (1999) · European Journal of Pediatrics · doi:10.1007/s004310051261 · Cited by 69
Simon, D. I., Brosius, F. C., & Rothstein, D. M. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.11.2379 · Cited by 69
Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy
Resor, S. R., & Resor, L. D. (1990) · Neurology · doi:10.1212/wnl.40.11.1677 · Cited by 67
Oxalic acid excretion after intravenous ascorbic acid administration
Robitaille, L., Mamer, O. A., Miller, W. H., Levine, M., Assouline, S., Melnychuk, D., Rousseau, C., & Hoffer, L. J. (2009) · Metabolism · doi:10.1016/j.metabol.2008.09.023 · Cited by 67
Pathological calcifications and selected examples at the medicine–solid-state physics interface
Bazin, D. C., & Daudon, M. (2012) · Journal of Physics D Applied Physics · doi:10.1088/0022-3727/45/38/383001 · Cited by 66
Self-citationNephrotoxicity as a Complication of Antiretroviral Therapy
Valle, R., & Haragsim, L. (2006) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2006.04.011 · Cited by 65
Schmid, S., Opravil, M., Möddel, M., Huber, M., Pfammatter, R., Keusch, G., Ambühl, P. M., Wuthrich, R. P., Moch, H., & Varga, Z. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0418-3 · Cited by 64
Alon, U. S., Scagliotti, D., & Garola, R. E. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70143-1 · Cited by 64
Hu, H., Zhang, J., Lu, Y., Zhang, Z., Qin, B., Gao, H., Wang, Y., Zhu, J., Wang, Q., Zhu, Y., et al. (2017) · Nutrients · doi:10.3390/nu9030301 · Cited by 64
Protease Inhibitors for HIV Infection
Bartlett, J. G. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-12-199606150-00011 · Cited by 63
Demographics and Characterization of 10,282 Randall Plaque-Related Kidney Stones: A New Epidemic?
Letavernier, E., Vandermeersch, S., Traxer, O., Tligui, M., Baud, L., Ronco, P. M., Haymann, J., & Daudon, M. (2015) · Medicine · doi:10.1097/md.0000000000000566 · Cited by 63
Self-citationBurger, D. M., Hugen, P. W. H., Aarnoutse, R. E., Dieleman, J. P., Prins, J. M., van der Poll, T., ten Veen, J. H., Mulder, J. W., Meenhorst, P. L., Blok, W. L., et al. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200103010-00003 · Cited by 63
PARFITT, A. M. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.124.6.736 · Cited by 63
INCREASED PREVALENCE AND ANALYSIS OF RISK FACTORS FOR INDINAVIR NEPHROLITHIASIS
Saltel, E., Angel, J. B., Futter, N. G., Walsh, W., O’Rourke, K., & Mahoney, J. E. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)66911-x · Cited by 62
Engeler, D. S., John, H. A., Rentsch, K., Ruef, C., Oertle, D., & Suter, S. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)65307-4 · Cited by 61
Nephrolithiasis in topiramate users
Maalouf, N. M., Langston, J. P., Ness, P. C. V., Moe, O. W., & Sakhaee, K. (2010) · Urological Research · doi:10.1007/s00240-010-0347-5 · Cited by 60
Secondary oxalosis due to excess vitamin C intake
Nasr, S. H., Kashtanova, Y., Levchuk, V., & Markowitz, G. S. (2006) · Kidney International · doi:10.1038/sj.ki.5001724 · Cited by 60
METABOLIC RISK FACTORS FOR STONE FORMATION IN PATIENTS WITH CYSTIC FIBROSIS
Pérez-Brayfield, M. R., Caplan, D. B., Gatti, J. M., Smith, E. A., & Kirsch, A. J. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(01)69068-2 · Cited by 60
Renal Atrophy Associated with Long-Term Treatment with Indinavir
Hanabusa, H., Tagami, H., & Hataya, H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902043400515 · Cited by 59
Acute Renal Failure Due to Ciprofloxacin
Allon, M., Lopez, E. J., & Min, K. W. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390210141030 · Cited by 59
Increased propensity for calcium phosphate kidney stones with topiramate use
Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.5.547 · Cited by 59
Atazanavir crystal nephropathy
Izzedine, H., m’rad, M. B., Bardier–Dupas, A., Daudon, M., & Salmon, D. (2007) · AIDS · doi:10.1097/qad.0b013e3282f17503 · Cited by 58
Self-citationAcetazolamide and furosemide for posthemorrhagic hydrocephalus of the newborn
Libenson, M. H., Kaye, E. M., Rosman, N. P., & Gilmore, H. E. (1999) · Pediatric Neurology · doi:10.1016/s0887-8994(98)00127-1 · Cited by 58
Guaifenesin- and Ephedrine-Induced Stones
Assimos, D. G., Langenstroer, P., LEINBACH, R. F., Mandel, N. S., STERN, J. M., & Holmes, R. P. (1999) · Journal of Endourology · doi:10.1089/end.1999.13.665 · Cited by 58
Smith, D. E., Jeganathan, S., & Ray, J. E. (2006) · HIV Clinical Trials · doi:10.1310/0kx0-h9vh-99ee-5d0l · Cited by 58
AMMONIUM ACID URATE CALCULI: A REEVALUATION OF RISK FACTORS
Soble, J. J., Hamilton, B. D., & Streem, S. B. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)61794-4 · Cited by 58
Increased Incidence of Indinavir Nephrolithiasis in Patients with Hepatitis B or C Virus Infection
Malavaud, B. A., Dinh, B., Bonnet, É., Izopet, J., Payen, J., & Marchou, B. (2000) · Antiviral Therapy · doi:10.1177/135965350000500105 · Cited by 57
Triamterene-Induced Nephrolithiasis
Ettinger, B. B., Weil, E., Mandel, N. S., & Darling, S. E. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-745 · Cited by 57
Topiramate increases biochemical risk of nephrolithiasis
Lamb, E. J., Stevens, P. E., & Nashef, L. (2004) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/000456304322880104 · Cited by 56
Ciprofloxacin Crystal Nephropathy
Stratta, P., Lazzarich, E., Canavese, C., Bozzola, C., & Monga, G. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.05.014 · Cited by 56
HIV medication-based urolithiasis
Izzedine, H., Lescure, F.-X., & Bonnet, F. (2014) · Clinical Kidney Journal · doi:10.1093/ckj/sfu008 · Cited by 56
Pais, V. M., Lowe, G. F., Lallas, C. D., Preminger, G. M., & Assimos, D. G. (2006) · Urology · doi:10.1016/j.urology.2005.10.057 · Cited by 56
(1998) · International Journal of STD & AIDS · doi:10.1258/0956462981922728 · Cited by 55
Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients
Brodie, S. B., Keller, M. J., Ewenstein, B. M., & Sax, P. E. (1998) · AIDS · doi:10.1097/00002030-199818000-00012 · Cited by 55
Acyclovir-induced renal failure: course and risk factors
Bianchetti, M. G., Roduit, C., & OETLIKER, O. H. (1991) · Pediatric Nephrology · doi:10.1007/bf01095963 · Cited by 54
Acetazolamide‐induced nephrolithiasis: Implications for treatment of neuromuscular disorders
Tawil, R., Moxley, R. T., & Griggs, R. C. (1993) · Neurology · doi:10.1212/wnl.43.6.1105 · Cited by 54
Kopp, J. B., Falloon, J., Filie, A. C., Abati, A. D., King, C., Hortin, G. L., Mican, J. M., Vaughan, E. M., & Miller, K. D. (2002) · Clinical Infectious Diseases · doi:10.1086/339486 · Cited by 54
ANTOPOL, W., & Robinson, H. J. (1939) · Experimental Biology and Medicine · doi:10.3181/00379727-40-10441p · Cited by 54
Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child
Prince, J. S., & Senac, M. O. (2003) · Pediatric Radiology · doi:10.1007/s00247-003-0963-0 · Cited by 53
Acute Taxol nephrotoxicity: Histological and ultrastructural studies of mice kidney parenchyma
Rabah, S. (2010) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2010.02.003 · Cited by 53
Katayama, F., Miura, H., & Takanashi, S. (2002) · Brain and Development · doi:10.1016/s0387-7604(02)00003-7 · Cited by 53
Absence of Oxalobacter Formigenes in Cystic Fibrosis Patients: A Risk Factor for Hyperoxaluria
Sidhu, H., Hoppe, B., Hesse, A., Tenbrock, K., Bromme, S., Rietschel, E., & Peck, A. B. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)69046-5 · Cited by 53
Antacid-Induced Osteomalacia and Nephrolithiasis
Cooke, N. E. (1978) · Archives of Internal Medicine · doi:10.1001/archinte.138.6.1007 · Cited by 52
Atazanavir urinary stones in an HIV-infected patient
Pacanowski, J., Poirier, J., Petit, I., Meynard, J., & Girard, P. (2006) · AIDS · doi:10.1097/01.aids.0000247571.88256.90 · Cited by 52
Urinary-Tract Stones Resulting from the Excretion of Oxypurinol
Landgrebe, A. R., Nyhan, W. L., & Coleman, M. (1975) · New England Journal of Medicine · doi:10.1056/nejm197503202921208 · Cited by 52
Clinical Pharmacology of the Loop Diuretics Furosemide and Bumetanide in Neonates and Infants
Pacifici, G. M. (2012) · Pediatric Drugs · doi:10.2165/11596620-000000000-00000 · Cited by 52
Kleinknecht, D., Landais, P., & Goldfarb, B. (1987) · Journal of Critical Care · doi:10.1016/0883-9441(87)90105-5 · Cited by 52
Ceftriaxone crystallization and its potential role in kidney stone formation
Chutipongtanate, S., & Thongboonkerd, V. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.053 · Cited by 52
Urine Composition and Stone Formation During Treatment with Acetazolamide
Ahlstrand, C., & Tiselius, H. (1987) · Scandinavian Journal of Urology and Nephrology · doi:10.3109/00365598709180326 · Cited by 52
Levine, B., Rodman, J., Wienerman, S., Rs, B., Lane, J., & Chapman, D. (1994) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/60.4.592 · Cited by 52
Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis?
Höppe, B., Hesse, A., Brömme, S., Rietschel, E., & Michalk, D. V. (1998) · Pediatric Nephrology · doi:10.1007/s004670050452 · Cited by 51
Incidence and risk factors for the development of indinavir-associated renal complications
Herman, J. S., Ives, N. J., Nelson, M., Gazzard, B. G., & Easterbrook, P. J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.3.355 · Cited by 51
Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Rho, M., & Perazella, M. A. (2007) · Current Drug Safety · doi:10.2174/157488607780598269 · Cited by 51
Indinavir crystal deposits associated with tubulointerstitial nephropathy
Martinez, F., Momméja-Marin, H., Estepa-Maurice, L., Beaufils, H., Bochet, M., Daudon, M., Deray, G., & Katlama, C. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.3.750 · Cited by 51
Self-citationHuman Geophagia, Calabash Chalk and Undongo: Mineral Element Nutritional Implications
Abrahams, P. W., Davies, T. C., Solomon, A. O., Trow, A. J., & Wragg, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053304 · Cited by 51
Amoxycillin, a rare but possible cause of crystalluria
Fogazzi, G. B., Cantù, M., Saglimbeni, L., & Daudon, M. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/18.1.212 · Cited by 51
Self-citationCiprofloxacin and Allergic Interstitial Nephritis
Rippelmeyer, D. J., & Synhavsky, A. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-2-170_1 · Cited by 50
Calcium and Phosphorus Regulatory Hormones and Risk of Incident Symptomatic Kidney Stones
Taylor, E. N., Hoofnagle, A. N., & Curhan, G. C. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07060714 · Cited by 50
Calcium oxalate kidney stones in patients on continuous ambulatory peritoneal dialysis
Oren, A., Husdan, H., Cheng, P., Khanna, R., Pierratos, A., Digenis, G. E., & Oreopoulos, D. G. (1984) · Kidney International · doi:10.1038/ki.1984.50 · Cited by 49
Xanthine Calculi in the Lesch-Nyhan Syndrome
Brock, W. A., Golden, J. A., & Kaplan, G. W. (1983) · The Journal of Urology · doi:10.1016/s0022-5347(17)51011-3 · Cited by 49
Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury
Durando, M., Tiu, H., & Kim, J. S. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.05.013 · Cited by 49
Wu, D. S.-H., & Stoller, M. L. (2000) · Current Opinion in Urology · doi:10.1097/00042307-200011000-00004 · Cited by 49
Carbone, L. G., Bendixen, B. H., & Appel, G. B. (1988) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(88)80076-3 · Cited by 48
Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient
Fam, A. G. (2001) · Current Rheumatology Reports · doi:10.1007/s11926-001-0048-8 · Cited by 48
High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients
LASTOURS, V. D., Silva, E. F. R. D., Daudon, M., Porcher, R., Loze, B., Sauvageon, H., & Molina, J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt125 · Cited by 48
Self-citationDaudon, M., Frochot, V., Bazin, D. C., & Jungers, P. (2016) · Comptes Rendus Chimie · doi:10.1016/j.crci.2016.04.010 · Cited by 48
Self-citationEPHEDRINE NEPHROLITHIASIS ASSOCIATED WITH CHRONIC EPHEDRINE ABUSE
BLAU, J. J. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)62796-4 · Cited by 47
Estepa-Maurice, L., Hennequin, C., Marfisi, C., Bader, C. A., Lacour, B., & Daudon, M. (1996) · American Journal of Clinical Pathology · doi:10.1093/ajcp/105.5.576 · Cited by 47
Self-citationCALCULUS FORMATION AND URETERAL COLIC FOLLOWING ACETAZOLAMIDE (DIAMOX) THERAPY
Persky, L. (1956) · JAMA · doi:10.1001/jama.1956.62970170001005 · Cited by 46
Indinavir nephropathy revisited: A pattern of insidious renal failure with identifiable risk factors
Reilly, R. F., Tray, K., & Perazella, M. A. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.27732 · Cited by 46
Medullary nephrocalcinosis associated with long‐term furosemide abuse in adults
Kim, Y.-G., Kim, B., Kim, M., Chung, S. J., Han, H., Ryu, J., Lee, Y., Lee, K., Lee, J. Y., Huh, W., et al. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.12.2303 · Cited by 46
Research works printed but not linked: 18
- Réveillaud RJ, Daudon M. Les lithiases urinaires médicamenteuses. Sémin Uro-Néphrol. 1986;12:14–39.
- Nguyen Quy D, Daudon M. Infrared and Raman spectra of calculi. Paris: Elsevier; 1997.
- Daudon M. Méthodes d’analyse des calculs et des cristaux urinaires. Classification morpho-constitutionnelle des calculs. In: Jungers P, Daudon M, Le Duc A, editors. Lithiase urinaire. Paris: Flammarion Médecine-Sciences; 1989. p. 35–113.
- Asper R. Iatrogenic urinary calculi: detection and identification by X-ray diffraction. Clin Chem. 1986;24:767–8.
- Daudon M, Estepa L, Viard JP, et al. Indinavir crystalluria in HIV-positive patients treated with indinavir sulfate. In: Rodgers AL, Hibbert BE, Hess B, Khan SR, Preminger GM, editors. Urolithiasis 2000, vol. I. Rondebosh: University of Cape Town; 2000. p. 335–7.
- Daudon M, Jungers P, Lacour B. Intérêt clinique de l’étude de la cristallurie. Ann Biol Clin. 2004;62:379–93.
- Daudon M, Estepa L, Labro B, et al. Infrared analysis of urinary calculi from animals [in French]. Eurobiol. 1998;236:243–55.
- Hammarsten G, Helldorff I, Magnusson W, et al. Dubbelsidiga njurstenar av kiselsyra efter bruk av silikathaltigt antacidum. Svensk Lakartiduing. 1953;50:1242–6.
- Hammarsten G. Terapi-inducerade urinvOagskonkrement. Opuscula Medica. 1958;3(1):19–22.
- Gaultier M, Bismuth C, Efthymiou ML, et al. Néphropathie tubulo-interstitielle aiguë au cours d’une intoxication par la glafénine. Nouv Presse Méd. 1975;1:3125.
- Volpe P, Peyrottes A, Lammle M, et al. Calcul urinaire de xanthine chez un patient porteur d’un syndrome de Lesch Nyhan. A propos d’un cas. Prog Urol. 1997;7(1):74–7.
- Cifuentes I, Bellanato J, Arquillué A, et al. Presencia de acido oxolinico en un calculo renal. Arch Esp Urol. 1986;39(5):369–73.
- Menzi P. Furadantin-Stein in einer Ureterozele. Helvet Chir. 1970;37(4/5):538–40.
- Zupancic M, Bukovec P. Complexation of magnesium (II) with ciprofloxacin and norfloxacin. Act Pharm. 1996;46:221–8.
- Parent X, Schieffer F. Felbamate crystalluria [in French]. Ann Biol Clin (Paris). 2010;68(5):609–13.
- Golematis B, Hatzitheofilou C, Dreiling DA, et al. The incidence of urolithiasis in pepticulcer patients. Am J Gastroenterol. 1977;68:367–71.
- Navas P, Grasset D. Anurie par lithiase urétérale urique bilatérale au cours d’un traitement par l’Amplivix. J Urol Néphrol. 1973;79:466–9.
- Matzkies F. Wirkungen und Nebenwirkungen von Benzbromaron bei der Initialbehandlung von Hyperurikämie und Gicht. Ergebnisse eines Feldversuches mit 3899 Patienten. Fortschr Med. 1978;96(32):1619–21.
Cited by
Drug-Induced Acute Kidney Injury
Perazella, M. A., & Rosner, M. H. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11290821 · Cited by 357
“As such, urine sediment examination for sulfa-drug–related crystals and casts is recommended to detect crystalline nephropathy when AKI develops (97,98).”
BackgroundRecent advances on the mechanisms of kidney stone formation (Review)
Wang, Z., Zhang, Y., Zhang, J., Deng, Q., & Liang, H. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4982 · Cited by 289
Kidney Stone Pathophysiology, Evaluation and Management: Core Curriculum 2023
Shastri, S., Patel, J. D., Sambandam, K. K., & Lederer, E. D. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.03.017 · Cited by 303
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Multiple Pathways for Pathological Calcification in the Human Body
Vidavsky, N., Kunitake, J. A. M. R., & Estroff, L. A. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001271 · Cited by 128
Metadata
- Authors
- Daudon, M., Frochot, V., Bazin, D., & Jungers, P.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Daudon, Michel
- Venue
- Drugs
- Published
- 2017-12-20
- Volume
- 78
- Issue
- 2
- Pages
- 163-201
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2781125041
- Cited by
- 191
- References
- 481
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 28 · 2023: 28 · 2022: 36 · 2021: 24 · 2020: 19 · 2019: 10 · 2018: 6 · 2017: 1
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Urology › Kidney Stones and Urolithiasis Treatments
- Health Sciences › Medicine › Nephrology › Nephrotoxicity and Medicinal Plants
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- drug-induced nephrolithiasis, crystalline nephropathy, kidney stones, urinary calculi, crystalluria, atazanavir, protease inhibitors, sulfadiazine, ceftriaxone, ephedrine, acute kidney injury, urine pH, calcium and vitamin D supplementation, carbonic anhydrase inhibitors, acetazolamide, topiramate, stone prevention, stone composition analysis
- MeSH terms
- Crystallization, Humans, Kidney Calculi, Risk Factors, Solubility, Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions, Renal Elimination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.